Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04670614
Other study ID # 15-15700
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 15, 2017
Est. completion date December 25, 2018

Study information

Verified date December 2020
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, randomized, blinded, sham controlled regional anesthetic (supra-orbital and infra-orbital nerve block) pain study to compare the systemic postoperative pain medication requirements in patients having Trans-sphenoidal Pituitary surgery. The patients will receive general anesthesia +/- regional anesthesia for trans-sphenoidal pituitary surgery and systemic pain medication during the intra-operative and postoperative (6hrs) period. The amount of systemic pain medication requirements will be compared between those patients receiving regional and general anesthesia versus general anesthesia alone.


Description:

Combined regional and general anesthesia for surgery is known to provide superior pain control in the peri-operative period (intra and post-operative). Of particular interest in neurosurgery are more rapid patient awakening and earlier ability to perform adequate post-operative neurological exam. In addition to this, regional anesthesia can decrease the total amount of systemic pain medications necessary and thus decrease their associated side effects. Consequently, less systemic pain medications can benefit the patient in many ways. By modifying the postop pain regime to include intraoperative regional anesthesia, there could be increased patient satisfaction, and significant economic gains to the hospital through a more streamlined, shorter, more pleasant hospital course for the patient. Patients who have this trans-sphenoidal pituitary surgery are usually same day admission patients who, following their surgery, are admitted for up to 24 hours postoperatively. Usually prolonged admissions result from headache and nausea +/- vomiting. Etiology of the headache is likely multifactorial. One theory is that stimulation of the peripheral trigeminal (Cranial Nerve Number V) fibers in the V1 and V2 distribution of the face by the surgical endoscope and surgical trauma may lead to release of inflammatory mediators and post-operative migraine. It has been shown that repetitive injection of local anesthetics in the distribution of supra-orbital nerve V1 and infra-orbital nerve V2 can decrease the incidence of chronic idiopathic migraine headaches not related to surgery. By administering regional anesthesia to the patient intra-operatively during their general anesthetic for the surgery, pain scores may be reduced, PONV (postoperative nausea and vomiting) decreased, and hospital stay shortened.This study will be examining the use of regional anesthesia (infra-orbital and supra-orbital nerve blocks) combined with general anesthesia versus general anesthesia to observe the systemic opioid consumptions of adult transsphenoidal pituitary surgery patients. Secondary endpoints of the study will be: (1) presence of PONV, (2) time in PACU (post anesthesia care unit) and finally, (3) duration of hospital stay until discharge.


Recruitment information / eligibility

Status Completed
Enrollment 49
Est. completion date December 25, 2018
Est. primary completion date December 25, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Adult age between 18 and 65 - American Society of Anesthesiology (ASA) 1-2 - Elective pituitary tumor surgery, tumor less than or equal to 2 cm diameter within the sella and no cavernous - sinus invasion - Single surgeon, Dr. Kunwar - Male and female patients - English speaking - Informed consent - Not on chronic pre-opertaive pain medications (non-narcotics) in the last 1 week prior to surgery - No opioid pain medications pre-op in the last 1 month before surgery - No abuse of recreational drugs (cocaine, methamphetamines, THC (tetrahydrocannabinol), opioids/heroin) - No herbal medications for pain in the 1-month prior to surgery Exclusion Criteria: - Age less than 18 years - Non-English speaking - Allergy to: Ropivicaine - Chronic pain condition, including idiopathic migraine as defined by the ICHD (International Classification of Headache Disorders) II criteria, requiring the use of pain medications - Inability to comprehend or adhere to study protocol

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Nerve Block with ropivicaine 0.5% Injectable Solution
Peripheral nerve blocks using 0.5% ropivicaine
Nerve Block with Placebo sham control of 0.9% Normal Saline
Peripheral Nerve Block with placebo 0.9% normal saline

Locations

Country Name City State
United States UCSF Moffitt Long Hospital San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary 6 hour post-operative Morphine Requirements in milligrams (mg) Systemic Intravenous (IV) morphine opioid consumption in mg in 2 groups during first 6 hours post-operatively (regional + general versus only general anesthesia) 6 hours post-op
Secondary Pain exposure postoperative for 6 hours Pain score out of max 10 (Scale 0-10). "O" (no Pain) and "10" (worst possible pain) 6 hours
Secondary Nausea and/or vomiting for 6 hours postoperatively Nausea score out of max 10 (Scale 0-10)."O" (no nausea) and "10" (worst nausea possible). Presence of vomiting is minimum score of 5/10. 6 hours
Secondary Time to discharge from Post anesthesia care unit (PACU) in minutes Time patient spends in PACU from entry time until discharge to the floor in minutes post-operative period measured in minutes up to 120 minutes
Secondary Time to discharge from hospital in minutes Time measured in minutes from surgery start to discharge from the hospital post-operative time up to 36 hours